Palvella Therapeutics, Inc.
Undisclosed program
Resolved
48days ago
Catalyst readout · May 20, 2026
What's at stake
A key catalyst for Undisclosed program (its lead indication) is expected May 20, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Palvella plans to submit an application to FDA for Breakthrough Therapy Designation in this indication.”